Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CVR Medical Corp CRRVF

CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool which complements other stroke screening technology, such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), and computed tomography angiography (CTA). The CSS is 100% non-invasive and does not require the use of harmful dyes. It offers its product to patients, payers, and healthcare providers. The CVR device uses only sound wave analysis to detect the presence of arterial stenosis.


GREY:CRRVF - Post by User

Bullboard Posts
Comment by buyifisell1on Dec 05, 2019 12:43pm
152 Views
Post# 30425528

RE:RE:RE:WEBSITE PRESENTATION + OVERALL CVR MED BULLBOARD

RE:RE:RE:WEBSITE PRESENTATION + OVERALL CVR MED BULLBOARD
Aquaman-

Many of us suspect that much of what Bakema did was in his personal best interest and not in the best interests of the shareholders. Work on his house? 30% loans?  The structure of the deal between Global and Medical?  But, there are two challenges: we don't know all of the details and, legally, a company is allowed tremendous latitude in running its business as it sees fit, no matter how clearly wrong it may be for the shareholders.

On the other hand, Bakema clearly did break the regulations in at least one case. Companies MUST notify their shareholders about news that is significant to the company.  In this case, we weren't officially notified about the May 31 meeting with FDA until late August. Anything more than 2 or 3 business days would be improper. Shortly after CVR made public the news of the May meeting, I filed a complaint with the BC Securities Commision. In it, I mention the very delayed news and asked if the trading suspension would nullify the need to report promptly (I was afraid there was some way to weasel out during a CTO.).  Here was their response...

"We have reviewed the information you provided in the complaint form, and appreciate you forwarding this information to us.  Requirements of securities law is independent of any Cease Trade Order (CTO) issued; in other words, no, a CTO does not exempt an issuer from their obligation to file press releases disclosing material changes in the company’s business."  It could be that the BCSC had something to say about Peter no longer being in charge as CEO and Chairman. Hell hath no fury like a bureaucrat scorned.

Bullboard Posts